The major finding of the current study was the elevated levels of DNAJC2-Ab in patients with atherosclerotic diseases, including stroke, AMI, DM, and CKD (Figures 2, 4, and 5, Table 3), which suggests that DNAJC2-Ab is potentially useful to evaluate the progress of atherosclerosis. This evidence concerns the gene DNAJC2 and diabetes mellitus.